白蛋白与平衡晶体液用于脓毒症早期复苏:开放平行组随机可行性试验——ABC-Sepsis试验
这项多中心、开放、平行组随机可行性试验在英国15家NHS医院急诊科开展,纳入脓毒症且国家早期预警评分2≥5分、需在随机后1小时内接受静脉液体的成人患者,比较平衡晶体液与5%人血白蛋白作为随机后最初6小时唯一早期复苏液。12个月内成功纳入301例,30天死亡率为17.9%(n=53);5%人血白蛋白组31例(21.1%)死亡,晶体液组22例(14.8%)死亡(校正OR 1.50;95%CI 0.84-2.83)。作者认为在该人群中开展确定性试验可行,但点估计提示该试验不太可能证明5%人血白蛋白作为脓毒症主要复苏液有显著获益。
要点
- 在英国15家NHS医院急诊科,12个月内纳入301例脓毒症患者,证明以5%人血白蛋白作为主要复苏液开展随机试验可行。
- 30天总死亡率17.9%(n=53);5%人血白蛋白组21.1%(31例) vs 平衡晶体液组14.8%(22例),校正OR 1.50(95%CI 0.84-2.83)。
- 随机后最初6小时内,分别以平衡晶体液或5%人血白蛋白作为唯一早期复苏液。
- 纳入标准为成人脓毒症、国家早期预警评分2≥5分、需在随机后1小时内接受静脉液体。
- 作者认为确定性试验可能可行,但点估计提示该试验不太可能证明5%人血白蛋白作为脓毒症主要复苏液有显著获益。
适用人群与场景
- 英国15家NHS医院急诊科收治的成人脓毒症患者,国家早期预警评分2≥5分,且需在随机后1小时内接受静脉液体。
诊断标准与关键阈值
- 纳入标准:成人脓毒症,国家早期预警评分2≥5分,需在随机后1小时内接受静脉液体。
处置流程与药物剂量
- 随机后最初6小时内,分别以平衡晶体液或5%人血白蛋白作为唯一早期复苏液进行静脉液体复苏。
研究设计与关键结果
- 多中心、开放、平行组随机可行性试验,在英国15家NHS医院急诊科开展,12个月内纳入301例;平均(标准差)年龄69岁(±16岁),男性151例(50%)。
- 筛查1303例,502例可能合格,300例随机接受试验干预,超过95%的参与者接受了干预;每中心中位参与者数19例(范围1-63例)。
- 30天死亡率为17.9%(n=53);5%人血白蛋白组31例(21.1%)死亡,晶体液组22例(14.8%)死亡(校正OR 1.50;95%CI 0.84-2.83)。
证据类型、等级与局限
- 证据类型:多中心、开放、平行组随机可行性试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在英国急诊科以5%人血白蛋白作为主要复苏液开展液体复苏试验是可行的。
- 作者认为,点估计提示确定性试验不太可能证明5%人血白蛋白作为脓毒症主要复苏液有显著获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: International guidelines recommend IV crystalloid as the primary fluid for sepsis resuscitation, with 5% human albumin solution (HAS) as the second line. However, it is unclear which fluid has superior clinical effectiveness. We conducted a trial to assess the feasibility of delivering a randomized controlled trial comparing balanced crystalloid against 5% HAS as sole early resuscitation fluid in patients with sepsis presenting to hospital.
DESIGN: Multicenter, open, parallel-group randomized feasibility trial.
SETTING: Emergency departments (EDs) in 15 U.K. National Health Service (NHS) hospitals.
PATIENTS: Adult patients with sepsis and a National Early Warning Score 2 greater than or equal to five requiring IV fluids withing one hour of randomization.
INTERVENTIONS: IV fluid resuscitation with balanced crystalloid or 5% HAS for the first 6 hours following randomization.
MEASUREMENTS AND MAIN RESULTS: Primary feasibility outcomes were recruitment rate and 30-day mortality. We successfully recruited 301 participants over 12 months. Mean ( sd ) age was 69 years (± 16 yr), and 151 (50%) were male. From 1303 participants screened; 502 participants were potentially eligible and 300 randomized to receive trial intervention with greater than 95% of participants receiving the intervention. The median number of participants per site was 19 (range, 1-63). Thirty-day mortality was 17.9% ( n = 53). Thirty-one participants died (21.1%) within 30 days in the 5% HAS arm, compared with 22 participants (14.8%) in the crystalloid arm (adjusted odds ratio, 1.50; 95% CIs, 0.84-2.83).
CONCLUSIONS: Our results suggest it is feasible to recruit critically ill patients to a fluid resuscitation trial in U.K. EDs using 5% HAS as a primary resuscitation fluid. There was lower mortality in the balanced crystalloid arm. Given these findings, a definitive trial is likely to be deliverable, but the point estimates suggest such a trial would be unlikely to demonstrate a significant benefit from using 5% HAS as a primary resuscitation fluid in sepsis.
参考来源
- Gray AJ, Oatey K, Grahamslaw J, et al. Albumin Versus Balanced Crystalloid for the Early Resuscitation of Sepsis: An Open Parallel-Group Randomized Feasibility Trial- The ABC-Sepsis Trial. Crit Care Med. 2024. PMID: 38912884. doi:10.1097/CCM.0000000000006348
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。